Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes

Diabetic Medicine

Volumn 23, Issue SUPPL. 1, 2006, Pages 14-19

  Levy, J C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1 [5,6,7,8 TETRAHYDRO 3 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRAZIN 7 YL] 4 (2,4,5 TRIFLUOROPHENYL) 1 BUTANONE; ALBUGON; CJC 1131; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG TOLERABILITY; GLUCAGON RELEASE; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; RISK FACTOR; STOMACH EMPTYING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; RECEPTORS, GLUCAGON; WEIGHT LOSS;

EID: 33645032922     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01833e.x     Document Type: Review

References (23)

1. Rachman J Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes Diabet Med 2004 21 (Suppl 1) 18 20
2. McIntyre N Holdsworth CD Turner DS New interpretation of oral glucose tolerance Lancet 1964 41 20 21
3. Nauck M Stockmann F Ebert R Creutzfeldt W Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 1986 29 46 52
4. Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 2002 359 824 830
5. Verdich C Flint A Gutzwiller JP Naslund E Beglinger C Hellstrom PM et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans J Clin Endocrinol Metab 2001 86 4382 4389
6. Drucker DJ Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis Endocrinology 2003 144 5145 5148
7. Madsbad S Schmitz O Ranstam J Jakobsen G Matthews DR Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial Diabetes Care 2004 27 1335 1342
8. Kim JG Baggio LL Bridon DP Castaigne JP Robitaille MF Jette L et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 2003 52 751 759
9. Baggio LL Huang Q Brown TJ Drucker DJ A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 2004 53 2492 2500
10. Ahren B Landin-Olsson M Jansson PA Svensson M Holmes D Schweizer A Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes J Clin Endocrinol Metab 2004 89 2078 2084
11. Ahren B Gomis R Standl E Mills D Schweizer A Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes Diabetes Care 2004 27 2874 2880
12. Mari A Sallas WM He YL Watson C Ligueros-Saylan M Dunning BE et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed {beta}-cell function in patients with type 2 diabetes J Clin Endocrinol Metab 2005 90 4888 4894
13. Kim D Wang L Beconi M Eiermann GJ Fisher MH He H et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005 48 141 151
14. Defronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 1100
15. Buse JB Henry RR Han J Kim DD Fineman MS Baron AD for the Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 2628 2635
16. Kendall DM Riddle MC Rosenstock J Zhuang D Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 1091
17. Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2005 143 559 569
18. Zander M Christiansen A Madsbad S Holst JJ Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes Diabetes Care 2004 27 1910 1914
19. Hanefeld M Herman G Mickel C McGowan A Wu M Zhao P Stein P Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes Diabetologia 2005 48 A287 (Abstract)
20. Scott R Herman G Zhao P Yee J De La Cruz J Wu L et al. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes Diabetologia 2005 48 A287 (Abstract)
21. Fineman MS Shen LZ Taylor K Kim DD Baron AD Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes Diabetes Metab Res Rev 2004 20 411 417
22. Maggs D Kim D Holcombe J Han J Shen L Ruggles J Fineman M Exenatide-induced reductions in A1c and body weight in long-term trials are not explained by gastrointestinal side effects Diabetes 2005 54 A120 (Abstract)
23. Kendall DM Kim D Poon T Han J Schnabel C Fineman M et al. Improvements in cardiovascular risk factors accompanied sustained effects on glycemia and weight reduction in patients with type 2 diabetes treated with exenatide for 82 weeks Diabetes 2005 54 A4 (Abstract)